期刊文献+

浅谈口服缓控释制剂在高血压治疗中的临床应用 被引量:1

Clinical Application of Orally Sustained Release Preparations in the Treatment of Hypertension
下载PDF
导出
摘要 目的促进临床更加安全、有效、合理的使用缓控释制剂。方法通过介绍缓控释制剂的剂型特点,以及在高血压治疗中临床应用所存在的诸多问题,了解常用的口服缓控释制剂的使用方法及注意事项。结果缓控释制剂在临床应用中存在用法、用量、给药频次等错误。结论临床药师加强药学监护,采取干预措施,使缓控释制剂的应用更安全、有效、合理。 Objective In order to promote clinical use of sustained and controlled release creparations more safely,effectively and reasonablely. Methods By introducing the characteristics of Sustained and controlled release preparations and some problems of clinical application in treatment of hypertension,to understand the commonly methods of use and matters needing attention. Results There were usage,dosage and frequency problems in the application. Conclusion The pharmaceutical care should be strengthened by clinical pharmacists and Interventions should be used to promote clinical use more safely,effectively and reasonablely.
作者 李艳凤
出处 《中国卫生标准管理》 2015年第28期100-101,共2页 China Health Standard Management
关键词 缓控释制剂 高血压 临床应用 Sustained and controlled release preparations Hypertension Clinical application
  • 相关文献

参考文献4

二级参考文献24

  • 1任君刚,邹梅娟,王悦,陈玉双,程刚.硝苯地平骨架缓释微丸的制备及在家犬体内的药物动力学[J].沈阳药科大学学报,2007,24(2):70-73. 被引量:13
  • 2陈丽华,冯怡,徐德生.中药缓控释微丸制剂的研究进展[J].中国中药杂志,2007,32(6):472-475. 被引量:20
  • 3全国卫生专业技术资格考试指导[M].北京:人民卫生出版社,2010:313.
  • 4Gunasekara N S,Noble S.Isosorbide 5-mononitrate:a review of asustained-release formulation (Imdur) in stable angina pectorisM[J].Drugs,1999,57(2):261-277.
  • 5Prakash A,Markham A.Long-acting isosorbide mononitrate[J].Drugs,1999,57(1):93-99.
  • 6Bhavane R,K arathana I E,Annapragada A V.Agg lom erated veicle technology:a new class of particle for controlled and modulated pulmonary drug delivery[J].J Controlled Rel,2003,93(1):15-28.
  • 7V idgren M,W a ldrep J C,A rppe J,et al.A study of Technetium labeled become thasone dip ropionate dilauroylphophatidylcholine liposome aerosol in normal volunteer[J].Int J Pharm,1995,115(2):209-216.
  • 8T eng C L,W ang T W,Dong G C,et al.Development of gelatin nanoparticles with biotiny-lated EGF conjugation for lung cancer targeting[J].Biomaterials,2007,28(27):3996-4005.
  • 9Hansen A,Pedersen CB.Severe respiratory depression after intake of a sustained-release morphine preparation[J].Ugeskr Laeger,1994,156(34):4834-4835.
  • 10Ayer A D,Swanson D R,Kuczynski A L.Dosage form for treating cardiovascular diseases[EB/OL].http:// www.wikipatents.com/ca/4950486.html,1990-08-21.

共引文献17

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部